A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetic Profile of OROS Hydromorphone in Healthy Adult Taiwanese Subjects Having Different Genotypes for the UGT2B7 Gene.
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2012
At a glance
- Drugs Hydromorphone (Primary)
- Indications Pain
- Focus Pharmacokinetics
- 17 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jan 2012 Actual patient number 29 added as reported by ClinicalTrials.gov.
- 12 Dec 2011 Planned end date changed from 1 Dec 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.